Immunotherapeutics Global Market – Forecast To 2021
Immunotherapy is the treatment given to suppress or amplify the immune response of a person using immunomodulators. The amplification of immune response is called as activation immunotherapy and the suppression of the immune response is called suppression immunotherapy. The global immunotherapeutics market is divided based on the segments, application and geography. Based on the segments, the immunotherapeutics are divided into monoclonal antibodies, vaccines, checkpoint inhibitors and non specific therapies. By application, the immunotherapeutics are divided into oncology, inflammatory disease, CNS and others. There are many cancer types such as lung cancer, melanoma, head and neck cancer, leukemia, colorectal cancer (CRC), lymphoma and others.
Geographical wise North America is the largest market, followed by Europe and Asia-pacific. The APAC regions suggest an array of opportunities for growth and are likely to be getting into the eyes of new investors in the immunotherapeutics market. Growth in the Asian market is attributed to rising incidence of target diseases, growing geriatric population and better healthcare initiatives by governments and various private organizations.
The immunotherapeutics global market is expected to grow at CAGR of 4.7% to reach $138.9 billion by 2021. The factors driving the growth of this market are increasing incidence of immunological diseases such as cancer, autoimmune diseases, high potency of immunotherapy drugs over small molecule drugs, mutual agreements among the companies for drug development to commercialization, adoption of biological therapies in disease management, increasing importance of CART therapies, market penetration of key players across emerging nations, commercialization and distribution of immunotherapy drugs. In addition to this, emerging Asia Pacific and Latin American countries engaging in immunotherapeutics development and increasing government funding are some of the opportunities that are propelling the growth of the market. However, the high cost of the drug development process with a threat of failure in the end stage and reimbursement issues are hampering the growth of the market. The threat to the immunotherapeutics market is reimbursement issue.
The global immunotherapeutics market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the immunotherapeutics market are AbbVie (U.S.), Amgen (U.S.), Biogen (U.S.), Bristol-Myers Squibb (U.S.), Celgene (U.S.), Johnson & Johnson (U.S.), Merck &Co., Inc (U.S.), Novartis (Switzerland), Pfizer (U.S.) and Roche (Switzerland).
Geographical wise North America is the largest market, followed by Europe and Asia-pacific. The APAC regions suggest an array of opportunities for growth and are likely to be getting into the eyes of new investors in the immunotherapeutics market. Growth in the Asian market is attributed to rising incidence of target diseases, growing geriatric population and better healthcare initiatives by governments and various private organizations.
The immunotherapeutics global market is expected to grow at CAGR of 4.7% to reach $138.9 billion by 2021. The factors driving the growth of this market are increasing incidence of immunological diseases such as cancer, autoimmune diseases, high potency of immunotherapy drugs over small molecule drugs, mutual agreements among the companies for drug development to commercialization, adoption of biological therapies in disease management, increasing importance of CART therapies, market penetration of key players across emerging nations, commercialization and distribution of immunotherapy drugs. In addition to this, emerging Asia Pacific and Latin American countries engaging in immunotherapeutics development and increasing government funding are some of the opportunities that are propelling the growth of the market. However, the high cost of the drug development process with a threat of failure in the end stage and reimbursement issues are hampering the growth of the market. The threat to the immunotherapeutics market is reimbursement issue.
The global immunotherapeutics market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the immunotherapeutics market are AbbVie (U.S.), Amgen (U.S.), Biogen (U.S.), Bristol-Myers Squibb (U.S.), Celgene (U.S.), Johnson & Johnson (U.S.), Merck &Co., Inc (U.S.), Novartis (Switzerland), Pfizer (U.S.) and Roche (Switzerland).
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKE AWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing incidence of immunological diseases such as cancer, autoimmune and infectious diseases
3.3.1.2 High potency of (antibodies) over small molecule drugs
3.3.1.3 Mutual agreements among companies from drug development to commercialization
3.3.1.4 Increasing importance of cart therapies
3.3.1.5 Adoption of biological therapies in disease management
3.3.1.6 Emerging asia pacific and latin american countries engaged in the development, commercialization and distribution of immunotherapy drugs
3.3.1.7 Increasing government funding
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 High cost of drug development process with a threat of failure in end stage
3.3.2.2 Reimbursement issues
3.4 PORTER’S FIVE FORCE ANALYSIS
3.4.1 THREAT OF NEW ENTRANTS
3.4.2 THREAT OF SUBSTITUTES
3.4.3 RIVALRY AMONG EXISTING COMPETITORS
3.4.4 BARGAINING POWER OF SUPPLIERS
3.4.5 BARGAINING POWER OF BUYERS
3.5 REGULATORY AFFAIRS
3.5.1 U.S.
3.5.2 EUROPE
3.5.3 CHINA
3.5.4 INDIA
3.5.5 JAPAN
3.6 REIMBURSMENT SCENARIO
3.7 PATENT ANALYSIS
3.8 MARKET SHARE ANALYSIS
4 IMMUNOTHERAPEUTICS GLOBAL MARKET, BY TYPE
4.1 INTRODUCTION
4.2 MONOCLONAL ANTIBODIES
4.2.1 NAKED MONOCLONAL ANTIBODIES
4.2.2 CONJUGATED MONOCLONAL ANTIBODIES
4.2.2.1 Radio-labeled antibodies
4.2.2.2 Chemo-labeled antibodies
4.2.3 BISPECIFIC MONOCLONAL ANTIBODIES
4.3 THERAPEUTIC VACCINES
4.4 CHECKPOINT INHIBITORS
4.5 NON-SPECIFIC IMMUNOTHERAPY
4.5.1 CYTOKINES
4.5.2 IMMUNOMODULATING DRUGS
5 IMMUNOTHERAPEUTICS GLOBAL MARKET, BY APPLICATION
5.1 INTRODUCTION
5.2 ONCOLOGY
5.2.1 LUNG CANCER
5.2.2 MELANOMA
5.2.3 HEAD AND NECK CANCER
5.2.4 LEUKEMIA
5.2.5 COLORECTAL CANCER
5.2.6 LYMPHOMA
5.2.7 OTHERS
5.2.7.1 Breast cancer
5.2.7.2 Myeloma
5.2.7.3 Bladder cancer
5.3 INFLAMMATION
5.4 CENTRAL NERVOUS SYSTEM
5.5 OTHERS
5.5.1 INFECTIOUS DISEASE
5.5.2 OPHTHALMOLOGY
5.5.3 BONE HEALTH
6 REGIONAL MARKET ANALYSIS
6.1 INTRODUCTION
6.2 NORTH AMERICA
6.3 EUROPE
6.4 ASIA PACIFIC
6.5 REST OF THE WORLD
7 COMPANY DEVELOPMENTS
7.1 INTRODUCTION
7.1.1 AGREEMENTS, COLLABORATIONS & PARTNERSHIPS AS MAJOR GROWTH STRATEGY OF PLAYERS
7.1.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES
7.2 APPROVALS
7.3 MERGERS AND ACQUISITIONS
7.4 OTHER DEVELOPMENTS
8 MAJOR PLAYER PROFILES
8.1 ABBVIE, INC.
8.1.1 OVERVIEW
8.1.2 FINANCIALS
8.1.3 PRODUCT PORTFOLIO
8.1.4 KEY DEVELOPMENTS
8.1.5 BUSINESS STRATEGY
8.1.6 SWOT ANALYSIS
8.2 AMGEN, INC.
8.2.1 OVERVIEW
8.2.2 FINANCIALS
8.2.3 PRODUCT PORTFOLIO
8.2.4 KEY DEVELOPMENTS
8.2.5 BUSINESS STRATEGY
8.2.6 SWOT ANALYSIS
8.3 BIOGEN
8.3.1 OVERVIEW
8.3.2 FINANCIALS
8.3.3 PRODUCT PORTFOLIO
8.3.4 KEY DEVELOPMENTS
8.3.5 BUSINESS STRATEGY
8.3.6 SWOT ANALYSIS
8.4 BRISTOL-MYERS SQUIBB
8.4.1 OVERVIEW
8.4.2 FINANCIALS
8.4.3 PRODUCT PORTFOLIO
8.4.4 KEY DEVELOPMENTS
8.4.5 BUSINESS STRATEGY
8.4.6 SWOT ANALYSIS
8.5 CELGENE
8.5.1 OVERVIEW
8.5.2 FINANCIALS
8.5.3 PRODUCT PORTFOLIO
8.5.4 KEY DEVELOPMENTS
8.5.5 BUSINESS STRATEGY
8.5.6 SWOT ANALYSIS
8.6 JOHNSON & JOHNSON
8.6.1 OVERVIEW
8.6.2 FINANCIALS
8.6.3 PRODUCT PORTFOLIO
8.6.4 KEY DEVELOPMENTS
8.6.5 BUSINESS STRATEGY
8.6.6 SWOT ANALYSIS
8.7 MERCK & CO, INC.
8.7.1 OVERVIEW
8.7.2 FINANCIALS
8.7.3 PRODUCT PORTFOLIO
8.7.4 KEY DEVELOPMENTS
8.7.5 BUSINESS STRATEGY
8.7.6 SWOT ANALYSIS
8.8 NOVARTIS AG
8.8.1 OVERVIEW
8.8.2 FINANCIALS
8.8.3 PRODUCT PORTFOLIO
8.8.4 KEY DEVELOPMENTS
8.8.5 BUSINESS STRATEGY
8.8.6 SWOT ANALYSIS
8.9 PFIZER, INC.
8.9.1 OVERVIEW
8.9.2 FINANCIALS
8.9.3 PRODUCT PORTFOLIO
8.9.4 KEY DEVELOPMENTS
8.9.5 BUSINESS STRATEGY
8.9.6 SWOT ANALYSIS
8.10 ROCHE
8.10.1 OVERVIEW
8.10.2 FINANCIALS
8.10.3 PRODUCT PORTFOLIO
8.10.4 KEY DEVELOPMENTS
8.10.5 BUSINESS STRATEGY
8.10.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKE AWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing incidence of immunological diseases such as cancer, autoimmune and infectious diseases
3.3.1.2 High potency of (antibodies) over small molecule drugs
3.3.1.3 Mutual agreements among companies from drug development to commercialization
3.3.1.4 Increasing importance of cart therapies
3.3.1.5 Adoption of biological therapies in disease management
3.3.1.6 Emerging asia pacific and latin american countries engaged in the development, commercialization and distribution of immunotherapy drugs
3.3.1.7 Increasing government funding
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 High cost of drug development process with a threat of failure in end stage
3.3.2.2 Reimbursement issues
3.4 PORTER’S FIVE FORCE ANALYSIS
3.4.1 THREAT OF NEW ENTRANTS
3.4.2 THREAT OF SUBSTITUTES
3.4.3 RIVALRY AMONG EXISTING COMPETITORS
3.4.4 BARGAINING POWER OF SUPPLIERS
3.4.5 BARGAINING POWER OF BUYERS
3.5 REGULATORY AFFAIRS
3.5.1 U.S.
3.5.2 EUROPE
3.5.3 CHINA
3.5.4 INDIA
3.5.5 JAPAN
3.6 REIMBURSMENT SCENARIO
3.7 PATENT ANALYSIS
3.8 MARKET SHARE ANALYSIS
4 IMMUNOTHERAPEUTICS GLOBAL MARKET, BY TYPE
4.1 INTRODUCTION
4.2 MONOCLONAL ANTIBODIES
4.2.1 NAKED MONOCLONAL ANTIBODIES
4.2.2 CONJUGATED MONOCLONAL ANTIBODIES
4.2.2.1 Radio-labeled antibodies
4.2.2.2 Chemo-labeled antibodies
4.2.3 BISPECIFIC MONOCLONAL ANTIBODIES
4.3 THERAPEUTIC VACCINES
4.4 CHECKPOINT INHIBITORS
4.5 NON-SPECIFIC IMMUNOTHERAPY
4.5.1 CYTOKINES
4.5.2 IMMUNOMODULATING DRUGS
5 IMMUNOTHERAPEUTICS GLOBAL MARKET, BY APPLICATION
5.1 INTRODUCTION
5.2 ONCOLOGY
5.2.1 LUNG CANCER
5.2.2 MELANOMA
5.2.3 HEAD AND NECK CANCER
5.2.4 LEUKEMIA
5.2.5 COLORECTAL CANCER
5.2.6 LYMPHOMA
5.2.7 OTHERS
5.2.7.1 Breast cancer
5.2.7.2 Myeloma
5.2.7.3 Bladder cancer
5.3 INFLAMMATION
5.4 CENTRAL NERVOUS SYSTEM
5.5 OTHERS
5.5.1 INFECTIOUS DISEASE
5.5.2 OPHTHALMOLOGY
5.5.3 BONE HEALTH
6 REGIONAL MARKET ANALYSIS
6.1 INTRODUCTION
6.2 NORTH AMERICA
6.3 EUROPE
6.4 ASIA PACIFIC
6.5 REST OF THE WORLD
7 COMPANY DEVELOPMENTS
7.1 INTRODUCTION
7.1.1 AGREEMENTS, COLLABORATIONS & PARTNERSHIPS AS MAJOR GROWTH STRATEGY OF PLAYERS
7.1.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES
7.2 APPROVALS
7.3 MERGERS AND ACQUISITIONS
7.4 OTHER DEVELOPMENTS
8 MAJOR PLAYER PROFILES
8.1 ABBVIE, INC.
8.1.1 OVERVIEW
8.1.2 FINANCIALS
8.1.3 PRODUCT PORTFOLIO
8.1.4 KEY DEVELOPMENTS
8.1.5 BUSINESS STRATEGY
8.1.6 SWOT ANALYSIS
8.2 AMGEN, INC.
8.2.1 OVERVIEW
8.2.2 FINANCIALS
8.2.3 PRODUCT PORTFOLIO
8.2.4 KEY DEVELOPMENTS
8.2.5 BUSINESS STRATEGY
8.2.6 SWOT ANALYSIS
8.3 BIOGEN
8.3.1 OVERVIEW
8.3.2 FINANCIALS
8.3.3 PRODUCT PORTFOLIO
8.3.4 KEY DEVELOPMENTS
8.3.5 BUSINESS STRATEGY
8.3.6 SWOT ANALYSIS
8.4 BRISTOL-MYERS SQUIBB
8.4.1 OVERVIEW
8.4.2 FINANCIALS
8.4.3 PRODUCT PORTFOLIO
8.4.4 KEY DEVELOPMENTS
8.4.5 BUSINESS STRATEGY
8.4.6 SWOT ANALYSIS
8.5 CELGENE
8.5.1 OVERVIEW
8.5.2 FINANCIALS
8.5.3 PRODUCT PORTFOLIO
8.5.4 KEY DEVELOPMENTS
8.5.5 BUSINESS STRATEGY
8.5.6 SWOT ANALYSIS
8.6 JOHNSON & JOHNSON
8.6.1 OVERVIEW
8.6.2 FINANCIALS
8.6.3 PRODUCT PORTFOLIO
8.6.4 KEY DEVELOPMENTS
8.6.5 BUSINESS STRATEGY
8.6.6 SWOT ANALYSIS
8.7 MERCK & CO, INC.
8.7.1 OVERVIEW
8.7.2 FINANCIALS
8.7.3 PRODUCT PORTFOLIO
8.7.4 KEY DEVELOPMENTS
8.7.5 BUSINESS STRATEGY
8.7.6 SWOT ANALYSIS
8.8 NOVARTIS AG
8.8.1 OVERVIEW
8.8.2 FINANCIALS
8.8.3 PRODUCT PORTFOLIO
8.8.4 KEY DEVELOPMENTS
8.8.5 BUSINESS STRATEGY
8.8.6 SWOT ANALYSIS
8.9 PFIZER, INC.
8.9.1 OVERVIEW
8.9.2 FINANCIALS
8.9.3 PRODUCT PORTFOLIO
8.9.4 KEY DEVELOPMENTS
8.9.5 BUSINESS STRATEGY
8.9.6 SWOT ANALYSIS
8.10 ROCHE
8.10.1 OVERVIEW
8.10.2 FINANCIALS
8.10.3 PRODUCT PORTFOLIO
8.10.4 KEY DEVELOPMENTS
8.10.5 BUSINESS STRATEGY
8.10.6 SWOT ANALYSIS
LIST OF TABLES
Table 1 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 2 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE, (2013-2021) ($MN)
Table 3 MONOCLONAL ANTIBODIES GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 4 THERAPEUTIC VACCINES GLOBAL MAREKT REVENUE, BY REGION, (2013-2021) ($MN)
Table 5 CHECKPOINT INHIBITORS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 6 NON-SPECIFIC IMMUNOTHERAPY GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 7 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN)
Table 8 ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 9 TOP SELLING DRUGS IN ONCOLOGY SEGMENT OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
Table 10 INFLAMMATION GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 11 TOP SELLING DRUGS IN INFLAMMATION OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
Table 12 CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 13 TOP SELLING DRUGS IN CNS OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
Table 14 OTHERS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 15 TOP SELLING DRUGS IN OTHERS OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
Table 16 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2014-2015)
Table 17 APPROVALS, (2014-2015)
Table 18 MERGERS AND ACQUISITIONS, (2014-2015)
Table 19 OTHER DEVELOPMENTS (2015)
Table 20 ABBVIE, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 21 ABBVIE, INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 22 ABBVIE, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 23 AMGEN, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 24 AMGEN, INC.: TOTAL REVENUE, BY PRODUCT TYPE, (2012-2014) ($MN)
Table 25 AMGEN, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 26 BIOGEN: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 27 BIOGEN: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 28 BRISTOL-MYERS SQUIBB: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 29 BRISTOL-MYERS SQUIBB: TOTAL REVENUE, BY PRODUCT, (2012-2014) ($MN)
Table 30 BRISTOL-MYERS SQUIBB: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 31 CELGENE: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 32 CELGENE: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 33 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 34 JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 35 JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 36 MERCK & CO., INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 37 MERCK & CO., INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 38 MERCK & CO., INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 39 NOVARTIS AG: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 40 NOVARTIS AG: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 41 NOVARTIS AG: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 42 PFIZER, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 43 PFIZER, INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 44 PFIZER, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 45 ROCHE: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 46 ROCHE: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 47 ROCHE: PHARMACEUTICALS REVENUE, BY APPLICATION, (2012-2014) ($MN)
Table 48 ROCHE: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 1 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 2 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE, (2013-2021) ($MN)
Table 3 MONOCLONAL ANTIBODIES GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 4 THERAPEUTIC VACCINES GLOBAL MAREKT REVENUE, BY REGION, (2013-2021) ($MN)
Table 5 CHECKPOINT INHIBITORS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 6 NON-SPECIFIC IMMUNOTHERAPY GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 7 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN)
Table 8 ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 9 TOP SELLING DRUGS IN ONCOLOGY SEGMENT OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
Table 10 INFLAMMATION GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 11 TOP SELLING DRUGS IN INFLAMMATION OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
Table 12 CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 13 TOP SELLING DRUGS IN CNS OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
Table 14 OTHERS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Table 15 TOP SELLING DRUGS IN OTHERS OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
Table 16 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2014-2015)
Table 17 APPROVALS, (2014-2015)
Table 18 MERGERS AND ACQUISITIONS, (2014-2015)
Table 19 OTHER DEVELOPMENTS (2015)
Table 20 ABBVIE, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 21 ABBVIE, INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 22 ABBVIE, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 23 AMGEN, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 24 AMGEN, INC.: TOTAL REVENUE, BY PRODUCT TYPE, (2012-2014) ($MN)
Table 25 AMGEN, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 26 BIOGEN: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 27 BIOGEN: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 28 BRISTOL-MYERS SQUIBB: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 29 BRISTOL-MYERS SQUIBB: TOTAL REVENUE, BY PRODUCT, (2012-2014) ($MN)
Table 30 BRISTOL-MYERS SQUIBB: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 31 CELGENE: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 32 CELGENE: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 33 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 34 JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 35 JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 36 MERCK & CO., INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 37 MERCK & CO., INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 38 MERCK & CO., INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 39 NOVARTIS AG: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 40 NOVARTIS AG: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 41 NOVARTIS AG: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 42 PFIZER, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 43 PFIZER, INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 44 PFIZER, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 45 ROCHE: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 46 ROCHE: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 47 ROCHE: PHARMACEUTICALS REVENUE, BY APPLICATION, (2012-2014) ($MN)
Table 48 ROCHE: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
LIST OF FIGURES
Figure 1 IMMUNOTHERAPEUTICS GLOBAL MARKET SHARE, BY REGION, (2013-2021) ($MN)
Figure 2 RESEARCH METHODOLOGY: IMMUNOTHERAPEUTICS MARKET
Figure 3 IMMUNOTHERAPEUTICS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
Figure 4 IMMUNOTHERAPEUTICS MARKET: FORECASTING MODEL
Figure 5 IMMUNOTHERAPEUTICS MARKET: MARKET CRACHDOWN AND DATA TRIANGULATION
Figure 6 IMMUNOTHERAPEUTICS GLOBAL MARKET: MARKET SEGMENTATION
Figure 7 MARKET DYNAMICS
Figure 8 IMMUNOTHERAPEUTICS MARKET: PORTER’S ANALYSIS
Figure 9 IMMUNOTHERAPEUTICS MARKET: PATENT FILLING BY MAJOR PLAYERS, (2011-2015)
Figure 10 IMMUNOTHERAPEUTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014
Figure 11 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE, (2014 V’S 2021) ($MN)
Figure 12 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2014 V’S 2021) ($MN)
Figure 13 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Figure 14 KEY GROWTH STRATEGIES, (2014-2015)
Figure 15 SWOT: ABBVIE, INC.
Figure 16 SWOT: AMGEN, INC.
Figure 17 SWOT: BIOGEN
Figure 18 SWOT: BRISTOL-MYERS SQUIBB
Figure 19 SWOT: CELGENE
Figure 20 SWOT: JOHNSON & JOHNSON
Figure 21 SWOT: MERCK & CO., INC.
Figure 22 SWOT: NOVARTIS AG
Figure 23 SWOT: PFIZER, INC.
Figure 24 SWOT: ROCHE
Figure 1 IMMUNOTHERAPEUTICS GLOBAL MARKET SHARE, BY REGION, (2013-2021) ($MN)
Figure 2 RESEARCH METHODOLOGY: IMMUNOTHERAPEUTICS MARKET
Figure 3 IMMUNOTHERAPEUTICS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
Figure 4 IMMUNOTHERAPEUTICS MARKET: FORECASTING MODEL
Figure 5 IMMUNOTHERAPEUTICS MARKET: MARKET CRACHDOWN AND DATA TRIANGULATION
Figure 6 IMMUNOTHERAPEUTICS GLOBAL MARKET: MARKET SEGMENTATION
Figure 7 MARKET DYNAMICS
Figure 8 IMMUNOTHERAPEUTICS MARKET: PORTER’S ANALYSIS
Figure 9 IMMUNOTHERAPEUTICS MARKET: PATENT FILLING BY MAJOR PLAYERS, (2011-2015)
Figure 10 IMMUNOTHERAPEUTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014
Figure 11 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE, (2014 V’S 2021) ($MN)
Figure 12 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2014 V’S 2021) ($MN)
Figure 13 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
Figure 14 KEY GROWTH STRATEGIES, (2014-2015)
Figure 15 SWOT: ABBVIE, INC.
Figure 16 SWOT: AMGEN, INC.
Figure 17 SWOT: BIOGEN
Figure 18 SWOT: BRISTOL-MYERS SQUIBB
Figure 19 SWOT: CELGENE
Figure 20 SWOT: JOHNSON & JOHNSON
Figure 21 SWOT: MERCK & CO., INC.
Figure 22 SWOT: NOVARTIS AG
Figure 23 SWOT: PFIZER, INC.
Figure 24 SWOT: ROCHE
